CytomX cuts ~40% of staff, $10M restructuring charge; COO, CFO, CMO to depart

CytomX Therapeutics, Inc.

Workforce reduction of ~40% primarily in development and G&A; completion expected by Q4 2022.
Estimated restructuring charges of ~$10M, mainly severance, recorded in Q3 and Q4 2022.
Cash runway extended into 2025 as a result of the restructuring.
President/COO Amy Peterson to leave effective Sept 12, 2022; CFO Carlos Campoy and CMO Alison Hannah effective Sept 30, 2022.
Company to prioritize pre-clinical/early clinical pipeline with two INDs planned for 2023.

item 2.05 item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Carlos Campoy

SVP, Chief Financial Officer

CTMX · CytomX Therapeutics, Inc.

Effective: 2022-09-30
Filed: July 13, 2022, 7:59 PM ET

the employment of Carlos Campoy, the Company’s SVP, Chief Financial Officer, and Alison Hannah, M.D., the Company’s SVP, Chief Medical Officer, is expected to terminate effective as of September 30, 2022

Departed

Alison Hannah

SVP, Chief Medical Officer

CTMX · CytomX Therapeutics, Inc.

Effective: 2022-09-30
Filed: July 13, 2022, 7:59 PM ET

the employment of Carlos Campoy, the Company’s SVP, Chief Financial Officer, and Alison Hannah, M.D., the Company’s SVP, Chief Medical Officer, is expected to terminate effective as of September 30, 2022

Departed

Amy Peterson

President and Chief Operating Officer

CTMX · CytomX Therapeutics, Inc.

Effective: 2022-09-12
Filed: July 13, 2022, 7:59 PM ET

the employment of Amy Peterson, M.D., the Company’s President and Chief Operating Officer, is expected to terminate effective September 12, 2022

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Carlos Campoy was terminated as SVP, Chief Financial Officer at CytomX Therapeutics, Inc..

Action: terminated
Role: SVP, Chief Financial Officer

Exact text from the filing

the employment of Carlos Campoy, the Company’s SVP, Chief Financial Officer, and Alison Hannah, M.D., the Company’s SVP, Chief Medical Officer, is expected to terminate effective as of September 30, 2022

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Alison Hannah was terminated as SVP, Chief Medical Officer at CytomX Therapeutics, Inc..

Action: terminated
Role: SVP, Chief Medical Officer

Exact text from the filing

the employment of Carlos Campoy, the Company’s SVP, Chief Financial Officer, and Alison Hannah, M.D., the Company’s SVP, Chief Medical Officer, is expected to terminate effective as of September 30, 2022

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Amy Peterson was terminated as President and Chief Operating Officer at CytomX Therapeutics, Inc..

Action: terminated
Role: President and Chief Operating Officer

Exact text from the filing

the employment of Amy Peterson, M.D., the Company’s President and Chief Operating Officer, is expected to terminate effective September 12, 2022

View on SEC.gov

CytomX Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-192874

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.